Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for children with severe atopic dermatitis [TSID10434]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC